---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127029"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:25:21.398398+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q3 net loss $43.9M, cash $197.9M; provides pipeline updates

## Summary
- Net loss of $43.9M ($0.84/sh) vs $50.0M ($0.95/sh) in Q3 2023; cash $197.9M expected to fund operations into 2026.
- Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet AMD) enrolling; enrollment completion targeted H1 2025.
- KSI-101 APEX study enrolling; dose selection for pivotal studies expected Q2 2025.
- Tarcocimab ocular half-life 20 days (3x faricimab, 2-3x aflibercept) presented at Sept R&D Day.
- Preclinical ABCD pipeline expanded to glaucoma and geographic atrophy programs.

## SEC filing metadata
- accession: 0000950170-24-127029
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017024127029/0000950170-24-127029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017024127029/kod-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127029
- JSON: https://secwatch.observer/filing/0000950170-24-127029.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.